Zacks Investment Research Lowers Zafgen, Inc. (ZFGN) to Hold
Zacks Investment Research cut shares of Zafgen, Inc. (NASDAQ:ZFGN) from a buy rating to a hold rating in a report issued on Saturday.
According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, ValuEngine upgraded Zafgen from a strong sell rating to a sell rating in a report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $6.38.
Shares of Zafgen (ZFGN) opened at 3.56 on Friday. Zafgen has a 12 month low of $2.89 and a 12 month high of $5.46. The stock’s market cap is $97.84 million. The company has a 50 day moving average of $3.47 and a 200 day moving average of $4.04.
Zafgen (NASDAQ:ZFGN) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. During the same period in the prior year, the firm earned ($0.55) earnings per share. Equities research analysts expect that Zafgen will post ($2.23) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/zacks-investment-research-lowers-zafgen-inc-zfgn-to-hold/1529032.html.
In other news, insider Dennis D. Kim bought 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The shares were bought at an average cost of $3.39 per share, for a total transaction of $33,900.00. Following the acquisition, the insider now directly owns 21,443 shares in the company, valued at $72,691.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 21.20% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Zafgen by 15.7% in the second quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock worth $3,102,000 after buying an additional 119,902 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Zafgen by 31.8% in the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock worth $2,050,000 after buying an additional 140,848 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Zafgen by 937.6% in the first quarter. JPMorgan Chase & Co. now owns 495,743 shares of the biopharmaceutical company’s stock worth $2,311,000 after buying an additional 447,964 shares in the last quarter. Spark Investment Management LLC boosted its position in shares of Zafgen by 49.5% in the second quarter. Spark Investment Management LLC now owns 282,200 shares of the biopharmaceutical company’s stock worth $990,000 after buying an additional 93,500 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its position in shares of Zafgen by 97.2% in the first quarter. Candriam Luxembourg S.C.A. now owns 213,000 shares of the biopharmaceutical company’s stock worth $993,000 after buying an additional 105,000 shares in the last quarter. Institutional investors own 48.52% of the company’s stock.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.